Objectives: To assess the Gram-positive-specific antibiotic linezolid and the broad-spectrum antibiotic tigecycline for use in local antibiotic delivery via antibiotic-loaded bone cement.
Introduction
Prosthetic joint infections present a rare but major complication in arthroplastic surgery. The incidence of infection across all arthroplastic procedures has been reported as ranging from 1% to 3%. 1 -3 Revision surgery to remedy an infected joint prosthesis is associated with increased costs, longer stays in hospital and potential morbidity, compared with revision surgery after aseptic failure. 4 -6 The number of arthroplastic procedures and the incidence of infection have increased over the last 10 years, as have the total costs associated with revision surgery. 4, 5, 7 As the demand for arthroplastic surgery progressively rises, the costs associated with prosthetic joint infection are set to increase greatly. This has led to perioperative antibiotic prophylaxis strategies, including the use of antibiotic-loaded bone cement, becoming routine. 8, 9 The management of a prosthetic joint infection involves removal of the infected prosthesis and radical debridement of the surrounding infected tissue. This is followed by either a onestage revision where a new prosthesis is implanted in a single procedure or a two-stage revision where a temporary spacer is used for several weeks before the new prosthesis is implanted.
In both procedures antibiotic therapy is standard practice, commonly combining systemic antibiotic treatment with local delivery using antibiotic-loaded bone cement. Antibiotic-loaded cement is used to cement the prosthesis into place and, in the two-stage revision, to form the temporary spacer. 10 Antibiotic-resistant organisms such as methicillin-resistant, vancomycin-resistant and MDR strains are increasingly becoming associated with prosthetic joint infections. More than 50% of all prosthetic joint infections are caused by staphylococci such as Staphylococcus aureus and Staphylococcus epidermidis and it has been estimated that around half of all S. aureus-related periprosthetic joint infections are now methicillin resistant. 1,11 -13 The ability of these organisms to acquire antibiotic resistance requires exploring the use of new antibiotics in bone cement.
Here we evaluate linezolid and tigecycline for use in antibioticloaded bone cement systems and assess their suitability for this application. There are few studies investigating the inclusion of linezolid in bone cement 14, 15 and, to our knowledge, there are no published data on the inclusion of tigecycline in bone cement. Linezolid is a member of the oxazolidinone family of antibiotics and is active against most Gram-positive organisms including 16 Tigecycline is a member of the glycylcycline family of antibiotics and has good activity against both Gram-negative and Gram-positive organisms. 17 
Materials and methods

Bacterial strains and growth conditions
All strains were maintained on Mueller -Hinton agar or Mueller -Hinton broth and grown overnight at 378C. Clinical isolates of S. aureus, S. epidermidis and Escherichia coli were isolated from infected prostheses at the Northern General Hospital, Sheffield. S. epidermidis DSM 3269 was purchased from the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ, Braunschweig, Germany). The S. aureus strain SH1000 was provided by Simon Foster, University of Sheffield.
Antimicrobial susceptibility
Serial dilutions of antibiotic standard solutions or serial dilutions of buffer from antibiotic elution experiments were prepared in triplicate with fresh Mueller -Hinton broth in 96-well microtitre plates. Wells were inoculated with each microorganism in triplicate to a final density of 10 5 cfu/mL and incubated overnight at 378C. MICs were determined by eye and were defined as the lowest concentration of antibiotic that showed complete inhibition of growth.
MG63 cell culture
Cells were cultured in EMEM containing 10% (v/v) FBS, 2 mM glutamine and 1% (v/v) non-essential amino acids. Cells were incubated at 378C (5% CO 2 ) and passaged three times a week.
MTT assay
MG63 cells were seeded at 2×10 3 cells per well in 100 mL EMEM containing the appropriate concentration of antibiotic. Cells were incubated at 378C (5% CO 2 ) for 48 h. After 48 h the medium was removed and fresh medium added. A 12 mM stock solution of MTT was prepared and 10 mL added to each well before incubating at 378C (5% CO 2 ) for 4 h. An SDS-HCl (100 mg/mL, 0.01 M HCl) stock solution was prepared and 100 mL added to each well before incubating for a further 4 h. Absorbance was measured at 570 nm and compared with positive control cultures containing no antibiotic.
Preparation of bone cement
Linezolid-, tigecycline-and gentamicin-containing bone cement samples were prepared by hand-mixing antibiotic powder (3% or 10% w/w) with Biomet Bone Cement R w powder until a homogeneous mix was produced. The antibiotic cement powder was then mixed with the appropriate amount of polymethylmethacrylate (PMMA) monomer liquid in a Hi-Vac bone cement mixing bowl (Biomet) as per the manufacturer's instructions. Refobacin Bone Cement R w and Bone cement R (Biomet) were also prepared in a Hi-Vac bone cement mixing bowl (Biomet) as per the manufacturer's instructions. The bone cement was placed into the relevant mould and allowed to cure for 1 h. Once removed from the mould, antibiotic-loaded cement samples were stored at 2208C for up to 1 week until required in order to preserve antibiotic activity. The storage of bone cement at this temperature was shown to have no appreciable effect on elution of antibiotic (data not shown).
Static elution of antibiotic from bone cement samples
Antibiotic-loaded bone cement was placed in circular moulds and allowed to cure for 1 h to produce a 31 mm diameter×7 mm thick disc. The resulting bone cement discs were then placed in 0.1 M ammonium acetate (pH 7.4) solution. This solution was stirred at 300 rpm in a UV-opaque container and 0.5 mL aliquots taken over 1 week and stored at 2208C until analysed.
Evaluation of the effect of wear on antibiotic elution
Evaluation of the effect of wear on the rate of elution of antibiotics from the bone cement was carried out via a procedure based on that described by Dodds et al., 18 as follows. The antibiotic-loaded bone cement was formed in an annulus-shaped mould and a 2 kg weight placed on top. The resulting annular samples were 40 mm outer diameter, 8 mm inner diameter and 10 mm thick. The sides of the annulus were coated with beeswax to ensure antibiotic could only elute from the outer perimeter. Controlled wear was generated by use of a high velocity oxygen fuel-vacuum plasma deposition (HVOF VPD) hydroxyapatite (HA)-coated 30 mm diameter×3 mm thick Ti disc which was placed onto the lever arm specimen holder of a TE-66 microabrasive wear tester. 16 The sample was orientated so that the flat 10 mm thick outer perimeter was in contact with the HA-coated counter-face and a 2.5 N force exerted by the counter-face onto the outer perimeter of the wearing cement sample. A container was placed beneath the assembly and filled with 0.1 M ammonium acetate solution (pH 7.4) until the lower portion of the cement sample was submerged. A magnetic stirrer was used to mix the solution in the container at 300 rpm and samples were rotated against the HA counter-face at 60 rpm for 51 h. The HA counter-face was repositioned every 10 -12 h to ensure a sufficiently abrasive counter-face throughout the experiment. An extension shaft was fitted to the TE-66 to allow simultaneous rotation of an unworn control sample at the same speed. This sample was also partially submerged in a separate container filled with 0.1 M ammonium acetate solution (pH 7.4). The experiment was placed in a UV-sealed air-tight container and the temperature and humidity constantly measured during the experiment. At regular intervals, 200 mL aliquots of solution were taken and stored at 2208C before analysis.
Quantification of antibiotics by LC-MS
Detection of linezolid was carried out on a Phenomenex Luna C 18 reversedphase column (150 mm×1 mm) attached to a Finnigan LCQ ion trap mass spectrometer. The isocratic mobile phase was 0.1% aqueous trifluoroacetic acid (TFA)/acetonitrile (77:23) and the flow rate was 0.05 mL/min. Measurement of linezolid concentration was carried out by monitoring the protonated parent ion at m/z 338.2 and comparing the results with a standard curve. Quantification of tigecycline was carried out as described above except the isocratic mobile phase was 0.1% aqueous TFA/methanol (67:33) and monitoring the protonated parent ion at m/z 586.5.
Impact strength analysis
The impact testing was carried out as described by Barker et al. 19 using a Charpy-type impact tester (Hounsfield Plastics impact testing apparatus). Antibiotic-loaded bone cement was moulded into 44.45 mm×7.93 mm×7.93 mm bars and notched using the Hounsfield notching machine (notch tip radius 0.25 mm). Impact analysis was carried out according to BS ISO 179-1:2010 specifications 20 with the exception of the specimen dimensions. For each sample group five specimens were made and force was applied to the un-notched side.
Statistical analysis
Statistical comparison of worn and unworn samples was carried out by unpaired t-test. The statistical analysis of impact testing samples was carried out by one-way analysis of variance. All statistical analysis was carried out using Microsoft Excel software.
Analysis of linezolid and tigecycline in bone cement
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Results
Elution of antibiotic from bone cement
Elution of antibiotic from bone cement samples containing 3% (w/w) linezolid or 3% (w/w) tigecycline was monitored over a 1 week period. The concentration of linezolid eluted from the bone cement increased over the 1 week time period of the experiment (Figure 1) . A maximum concentration of 12.2+2.9 mg/L linezolid was reached after 168 h and the initial elution rate of linezolid from bone cement was calculated as 213.4+33.4 mg/h/g bone cement. The concentration of eluted tigecycline initially increased to a maximum concentration of 0.66+0.35 mg/L after 1 h and then decreased to 0.084+0.025 mg/L after 24 h and 0.014+0.013 mg/L after 168 h (Figure 2 ). The initial elution rate of tigecycline from bone cement was calculated as 32.8+17.2 mg/h/g bone cement.
Effect of wear on elution of bone cement
The results from three separate experiments to investigate the effect of wear on the elution behaviour of cement containing 3% (w/w) tigecycline are shown in Figure 3 . The samples were collected over a 51 h period and the maximum concentration of eluted antibiotic was reached between 5 and 12 h. The highest concentration overall was seen in the unworn sample 2 after 12 h with a concentration of 2.1 mg/L compared with 0.1 mg/L in the worn counterpart (Figure 3b) . Although there was some variability in the maximum concentrations between the three experiments, in all cases a clear trend can be seen with the elution from unworn samples being significantly higher than from the worn bone cement samples (P,0.05). After 1 h the elution of tigecycline from unworn samples was 9.4+2.6 mg/h/cm 3 surface and the rate of elution from the worn samples was 2.3+2.5 mg/h/cm Nichol et al.
The results from three separate experiments to investigate the effect of wear on the elution behaviour of cement containing 3% (w/w) linezolid are shown in Figure 4 . The samples were collected over a 51 h period and the maximum concentration of eluted antibiotic was reached between 24 and 51 h with the concentration continuing to increase in all but one sample. The highest concentration overall was seen in the worn sample 2 after 51 h with a concentration of 53.1 mg/L (Figure 4b) . No significant difference can be seen in the elution kinetics between the worn and unworn linezolid samples (P ¼0.63). After 1 h the rate of elution from unworn linezolid samples was 232.5+22.4 mg/h/cm 3 surface and the rate of elution from the worn linezolid samples was 242.4+24.3 mg/h/cm 3 surface. The rates of antibiotic elution from both unworn and worn linezolid samples were .100-fold higher than that of the worn tigecycline samples and 24.8-and 25.9-fold higher respectively than the unworn tigecycline samples.
Antimicrobial activity of eluted antibiotics
S. aureus (SH1000), S. epidermidis (DSM 3269) and an S. epidermidis strain isolated from an infected prosthesis were used as test organisms to investigate whether the eluted antibiotics retained antimicrobial activity. The MICs for these strains with standard Analysis of linezolid and tigecycline in bone cement JAC solutions of the antibiotics are shown in Table S1 (available as Supplementary data at JAC Online). The concentrations of linezolid and tigecycline eluted at various times from antibiotic-loaded cement samples were determined via LC-MS and the MICs of the eluted antibiotics were determined experimentally (Tables 1 and  2 ). All eluted tigecycline samples showed activity comparable to the standard solution and established breakpoints 21, 22 for all organisms tested (Table 1 ). The linezolid samples eluted up to 72 h all showed activity comparable to determined MICs and breakpoints against the Gram-positive organisms. 21 The linezolid samples eluted over 1 week (168 h) showed higher MICs compared with the other samples and the Gram-negative E. coli was not inhibited by any of the linezolid samples, as expected ( Table 2) .
Cytotoxicity of antibiotics towards MG63 cells
The cytotoxic effects of standard solutions of linezolid and tigecycline against MG63 cells were determined using the MTT assay. The addition of increasing concentrations of tigecycline resulted in a marked reduction in cell activity with an IC 50 of between 5 and 10 mg/L. The addition of linezolid showed a small reduction in activity that was not statistically significant (P .0.05). Up to 300 mg/L linezolid resulted in ,50% reduction in cell activity and so an IC 50 for linezolid could not be determined ( Figure S1 , available as Supplementary data at JAC Online). A comparison of these results with the concentrations achieved in the elution experiments (Figures 1-4) suggests that the cellular toxicity of tigecycline may be an issue if the in vivo eluted concentrations are similar to those in this laboratory system, whereas linezolid did not show toxicity to mammalian cells, even at substantially higher concentrations than those achieved in the elution experiments.
Impact testing to assess physical strength of bone cement samples
A Charpy-type impact test machine was used to evaluate the impact strength of the antibiotic-loaded bone cement. Separate bone cement samples loaded either with tigecycline or linezolid at 3% and 10% (w/w) were tested, and the results compared with both bone cement without antibiotic and a commercially prepared gentamicin-loaded bone cement, Refobacin w Bone Cement R (Table 3 ). There was no significant difference in the impact strength of the tigecycline-loaded cement samples at either concentration, compared with the control without antibiotic. The 10% (w/w) tigecycline-loaded cement was the only cement that had an impact strength that appeared slightly lower than the bone cement without antibiotic; however, this difference was not statistically significant. Further, there was no significant difference between the linezolid-loaded samples at either concentration and the Refobacin w Bone cement R samples (P .0.05). The impact strengths of both the 3% and 10% (w/w) tigecycline cement samples were significantly less (P, 0.05) than, though still comparable to, the commercially available Refobacin w Bone Cement R.
Discussion
The results presented here indicate that tigecycline and linezolid can be included within bone cement and that the elevated temperatures that occur during the curing stage do not compromise their antimicrobial and biocompatibility properties. Both antibiotics elute to clinically relevant concentrations within the first hour in our laboratory elution system (Figures 1 and 2 ) and retain Experiments were carried out in triplicate. Experiments were carried out in triplicate.
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antimicrobial activity up to 1 week later. The concentrations of eluted tigecycline peaked around 1 h ( Figure 2 ) and then declined, presumably due to decomposition of the antibiotic. The MICs of eluted tigecycline based upon the concentrations measured by LC-MS showed results comparable to those determined using standard antibiotic solutions (Table 1 and Table S1 ). The MICs of eluted linezolid, the concentration of which increased progressively throughout the experiment (Figure 1) , were comparable to those determined using standard antibiotic solutions over the first 72 h. After 1 week, eluted linezolid showed 5 -20-fold higher MICs than the standard linezolid ( Table 2 and Table S1 ), which may indicate slow decomposition of the eluted antibiotic that was not revealed by LC-MS. Previously, Anagnostakos et al. 14 reported elution of 1% of total linezolid from bone cement, compared with 3% for gentamicin-loaded cement over 8 days, and Jackson et al. 15 reported up to 3% elution over a 4 week period. Cement containing linezolid and gentamicin has shown inhibited growth of MRSA for up to 8 days.
14 However, as this previous study involved linezolid in conjunction with gentamicin it does not necessarily confirm the activity of the linezolid on its own.
The effect of wear on the tigecycline-loaded bone cement samples significantly reduced the elution of tigecycline. After 1 h there was a .4-fold reduction in the elution rate from the worn sample, compared with the unworn control ( Figure 3 ). Conversely, wear had very little effect on the elution of linezolid from the bone cement, with similar elution rates and profiles for both worn and unworn samples (Figure 4 ). This may be relevant in the clinical application of these systems where the cement surface experiences wear. Previously we have reported similarly contrasting results with gentamicin-and daptomycin-loaded bone cements where elution of gentamicin was significantly reduced by wear, yet elution of daptomycin was not affected. 16 In that study it was suggested that crystal size and distribution were the two main factors influencing this difference in elution characteristics between the two antibiotics. It was observed that the larger crystals of gentamicin within the orthopaedic cement created voids on the surface upon contact with the aqueous solution, thus allowing greater deformation of the bone cement surface due to wear. It was further proposed that this deformation prevented the solution from penetrating deep into the bone cement, thereby limiting the amount of antibiotic that could be eluted. In the current study we have shown that the crystals of tigecycline are smaller than the linezolid crystals and so crystal size appears not to be the main factor determining the reduced elution from worn bone cement samples here ( Figure S1 ). However, there is a much greater tendency for the tigecycline crystals to aggregate within the cement compared with linezolid. The surface of the tigecycline-loaded cement showed areas of aggregated tigecycline crystals, which may also produce voids upon contact with the aqueous solution and so increase the deformation of the bone cement surface ( Figures S2 and S3 , available as Supplementary data at JAC Online).
The impact strength of the linezolid-and tigecycline-loaded cements produced results comparable to those of commercially available bone cements. The lowest impact strength was seen in the cement containing 10% tigecycline, suggesting that tigecycline may have some effect on the mechanical strength of the cement. A previous study by Kreis et al. 23 showed that the addition of tigecycline had a detrimental effect on the compressive and bending strength of tigecycline-loaded bone cement.
Kreis et al. 23 also mentioned a 3.8-fold increase in curing time compared with cement only. Curing time was not specifically investigated during the current study, but all cement samples were fully cured within ,1 h.
The MTT assay showed that linezolid had low cytotoxicity towards MG63 cells. Up to 300 mg/L linezolid resulted in ,50% loss of cell activity and so an IC 50 was not determined. Tigecycline showed greater cytotoxicity with an IC 50 of 5-10 mg/L. This result is consistent with the findings of Pina et al., 24 who also found that tigecycline concentrations .10 mg/L severely affected the cell growth of osteoblastic cells.
Conclusions
The antimicrobial activity of linezolid and tigecycline eluted from within bone cement reaches therapeutically relevant concentrations within the critical perioperative period (based on a typical arthroplasty operation of 1 -2 h). Antimicrobial activity is observed up to 1 week later. However, the concentration of tigecycline added to cement may need to be controlled due to the possible cytotoxicity of the eluted antibiotic towards osteoblast cells. The effect of wear in reducing elution of tigecycline in the laboratory reported here is also a factor to be borne in mind if this antibiotic is used in revision surgery. Owing to ongoing antibiotic resistance problems, there is a need to use antibiotics such as linezolid and tigecycline both alone and in conjunction with other antibiotics (such as gentamicin, which is included in commercial bone cement preparations currently widely used in arthroplasty surgery). The current study is an in vitro assessment of the performance and does not model the conditions in vivo. Upon implantation the prosthetic comes into contact with extracellular fluid, bone and muscle tissue, all of which will affect elution and the local accumulation of antibiotic. Further work assessing the in vivo performance of these cements as well as more mechanical testing needs to be carried out to fully evaluate these antibioticloaded cements. However, based on the results presented above we propose that linezolid and tigecycline are encouraging candidates for local delivery via antibiotic-loaded bone cement, in the treatment and prevention of prosthetic joint infection.
